



ARTICLE OPEN

Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT_{2A} receptors through Akt/mTOR pathway

Inés Ibarra-Lecue¹, Irene Mollinedo-Gajate¹, J Javier Meana^{1,2}, Luis F Callado^{1,2}, Rebeca Diez-Alarcia^{1,2} and Leyre Urigüen^{1,2}

Long-term use of potent cannabis during adolescence increases the risk of developing schizophrenia later in life, but to date, the mechanisms involved remain unknown. Several findings suggest that the functional selectivity of serotonin 2A receptor (5-HT_{2A}) through inhibitory G-proteins is involved in the molecular mechanisms responsible for psychotic symptoms. Moreover, this receptor is dysregulated in the frontal cortex of schizophrenia patients. In this context, studies involving cannabis exposure and 5-HT_{2A} are scarce. Here, we tested in mice the effect of an early chronic Δ^9 -tetrahydrocannabinol (THC) exposure on cortical 5-HT_{2A} expression, as well as on its in vivo and in vitro functionality. Long-term exposure to THC induced a pro-hallucinogenic molecular conformation of the 5-HT_{2A} and exacerbated schizophrenia-like responses, such as prepulse inhibition disruption. Supersensitive coupling of 5-HT_{2A} toward inhibitory Gai1-, Gai3-, Gao-, and Gaz-proteins after chronic THC exposure was observed, without changes in the canonical Gq/11-protein pathway. In addition, we found that inhibition of Akt/mTOR pathway by rapamycin blocks the changes in 5-HT_{2A} signaling pattern and the supersensitivity to schizophrenia-like effects induced by chronic THC. The present study provides the first evidence of a mechanistic explanation for the relationship between chronic cannabis exposure in early life and increased risk of developing psychosis-like behaviors in adulthood.

Neuropsychopharmacology (2018) 43:2028–2035; <https://doi.org/10.1038/s41386-018-0076-y>

INTRODUCTION

Cannabis consumption especially in early adolescence [1], a period of increased vulnerability to its effects, increases the risk of developing schizophrenia [2]. Both cannabis extracts and Δ^9 -tetrahydrocannabinol (THC) can evoke transient psychotic states in healthy subjects [3] and worsen symptoms in schizophrenia patients [4]. However, the neuronal and molecular mechanisms underlying psychotic symptoms elicited by cannabis abuse during adolescence remain unknown.

Several findings suggest that serotonin 2A receptors (5-HT_{2A}) are involved in the molecular mechanisms responsible for psychotic symptoms. In addition to the canonical signaling pathway through Gq/11-proteins, hallucinogenic 5-HT_{2A} agonists, such as lysergic acid diethylamide (LSD) and 2,5-dimethoxy-4-iodoamphetamine ((±)-DOI), which trigger mental states resembling psychotic symptoms [5] activate inhibitory Gai/o proteins [6]. Conversely, non-hallucinogenic 5-HT_{2A} agonists exclusively activate the canonical signaling pathway through Gq/11-proteins. This differential signaling mechanism responsible for the unique effects of hallucinogens is known as biased agonism.

The disruption of 5-HT_{2A} functionality in psychosis is supported by genetic studies describing differential epigenetic methylation and gene polymorphisms in subjects with schizophrenia [7]. Animal models of schizophrenia have shown increased 5-HT_{2A} density and/or functionality [8, 9]. Moreover, it has been demonstrated that the active conformation of the 5-HT_{2A} is up-regulated in prefrontal cortex of antipsychotic-free schizophrenia subjects [10]. Furthermore, atypical antipsychotics

display high affinity as antagonists of 5-HT_{2A}. All these data demonstrate that upregulation and/or increased functionality of 5-HT_{2A} could predispose to psychosis or schizophrenia.

Akt/mTOR signaling pathway mediates several functions, including synaptic plasticity and axonal branching [11]. Akt protein dysregulation has been linked to schizophrenia [12, 13], and, in addition, *AKT1* genetic variations have been associated with increased psychotic symptoms after smoking cannabis [14]. Importantly, acute THC activates this signaling pathway in mouse brain [15].

Considering these findings, we investigated whether chronic THC exposure at young ages could lead to an over-functionality of brain cortical 5-HT_{2A} with biased agonism toward pro-hallucinogenic G-protein pathways. In addition, the possible involvement of Akt/mTOR signaling pathway in the induction of this psychosis-like status was studied.

MATERIALS AND METHODS

Animals

All experimental procedures were performed in accordance with the European Directive for the Protection of Vertebrate Animals used for experimental and Other Scientific Purposes (European Union Directive 2010/63/EU) and approved by the Ethic Committee for Animal Welfare of the University of the Basque Country (UPV/EHU) (CEBA 270M/2012, 189/2011). Male CD-1 mice (Charles Rivers, Wilmington, MA, USA) were housed (6–8 animals per cage) under controlled temperature (23 ± 1 °C), on a normal 12 h light/dark cycle, with free access to food and water. Only male mice

¹Department of Pharmacology, University of the Basque Country UPV/EHU and Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, Leioa, Spain and

²Biocruces Health Research Institute, Bizkaia, Spain

Correspondence: Leyre Urigüen (leyre.uriguen@ehu.eus)

Received: 13 February 2018 Revised: 13 April 2018 Accepted: 15 April 2018

Published online: 27 April 2018

were used in this study to avoid the effects of the female estrous cycles that can interfere with the pharmacological parameters.

Treatments

THC, rapamycin and vehicle were administered for 30 days starting at postnatal day 21. Drugs were dissolved in ethanol:cremophor:saline (0.9% NaCl) at 1:1:18 ratio. THC (THCPharm. GmbH, Frankfurt, Germany) (10 mg/kg ip) [15] was injected daily. Rapamycin (Shelleck Chemicals LLC, Houston, TX, USA) (5 mg/kg ip) was administered in a 1 day on/1 day off schedule [16], 30 min before THC injection. For prepulse inhibition (PPI) experiments, (\pm)-DOI (Sigma-Aldrich, St. Louis, MO, USA) (0.5 mg/kg ip) [17] was dissolved in saline and administered immediately before the behavioral assay. Experiments were carried out after a 5-day washout period to avoid the interference of acute effects of THC.

Experimental design

Experimental design of each assay was conducted as follows. A first batch of two groups of animals (vehicle and THC, $n = 16$ animals per group) was treated with THC or vehicle for 30 days. After a 5-day washout period, a number of animals ($n = 8$ per group, vehicle and THC) were killed, brains removed and THC concentrations measured. The rest of the animals ($n = 8$ per group, vehicle and THC) were used to perform basal PPI, 5-HT_{2A}R density, radioligand binding and functional coupling experiments ($n = 8$ per group, pooled for in vitro assays). Briefly, after the 5-day washout period, PPI experiments were carried out and later, animals were killed, brains removed, and in vitro assays performed.

Another different batch of four groups of animals (vehicle-vehicle, vehicle-THC, rapamycin-vehicle and rapamycin-THC) ($n = 8$ per group) was established to carry out basal PPI, western blot experiments (Akt, p-Akt, rpS6, p-rpS6) and functional coupling experiments ($n = 8$ per group, pooled for in vitro assays) following these different pharmacological treatments.

Finally, another batch of four groups (vehicle-vehicle, vehicle-THC, rapamycin-vehicle and rapamycin-THC) was used to accomplish PPI experiments after acute DOI in a timely matched manner ($n = 8$ per group).

Quantification of THC concentration in mouse brain by liquid chromatography–tandem mass spectrometry

Pooled homogenized THC-free mouse brain samples ($n = 6–8$) were used for the development and validation. Experiments were carried out with a 1290 Infinity II ultrahigh performance liquid chromatography (UHPLC) system coupled to a 6495 iFunnel triple Quad mass spectrometer equipped with a JetStream electrospray ionization source (Agilent Technologies, Santa Clara, CA, USA). A Kinetex EVOC18 100A 3×100 mm (2.6 μ m) column was selected. Sample analysis in positive ionization mode was performed using as mobile phase water with 0.1% formic acid (solvent A) and acetonitrile with 0.1% formic acid (solvent B) with elution gradient mode. The flow rate was 0.5 ml/min; injection volume was 5 μ l, and the column temperature was maintained at 30 °C. The calibration curve was prepared by spiking 20 μ l of standard working solution to obtain brain THC final concentrations of 8–2000 ng/g. Quality control samples (QCs) were prepared by spiking brain samples containing 60 and 1000 ng/g as the final THC concentration.

Prepulse inhibition of the startle reflex

Prepulse inhibition (PPI) test was performed in a startle chamber (PanLab, Barcelona, Spain) where a 60-dB background-noise was present for a 10 min acclimatization period, as well as throughout the entire experiment. Each session began with five startle pulse-alone trials to achieve a more stable response of the animals and were not included in the analysis. Mice were then subjected to a pseudo-randomized combination of: ten pulse-alone trials

consisted of a white noise burst (120 dB, 40 ms); ten prepulse-alone trials for each prepulse intensity (10 ms at 77, 82, or 87 dB); ten prepulse-pulse trials for each prepulse intensity with an interval of 60 ms between both and ten no-stimulus trials, in which only the background noise was present. The inter-trial intervals were 10, 12, 15, 20, and 25 s. The maximum amplitude of the startle reaction was recorded for every trial, and the average startle for each trial subgroup was used for the analysis. No-stimulus trials and prepulse-alone trials did not exert any startle response and data were not included in the analysis. PPI was calculated as a percentage score: % PPI = $100 - [(\text{startle response to prepulse-pulse trial} / \text{startle response to pulse-alone trial}) \times 100]$. Inhibition of the PPI response was induced by administration of the 5-HT_{2A}R agonist (\pm)-DOI (0.5 mg/kg, i.p.) immediately before acclimation period. Each session lasted 30–33 min.

Brain cortex membranes preparation

Animals were killed by cervical dislocation, brains removed, cortex dissected, and samples stored at -80 °C until use. Membrane-enriched fraction (P2) was prepared as described [18].

Radioligand binding

[³H]Ketanserin saturation binding assays were performed as previously reported [19] with minor modifications. [³H]Ketanserin binding (0.05–10 nM; eight concentrations) was used to calculate density (B_{max}) and affinity (K_d) of 5-HT_{2A}R. Non-specific binding was determined in the presence of the 5-HT_{2A}R antagonist M100907 (1 μ M). Competition curves of [³H]ketanserin binding (2 nM) with increasing concentrations of the agonist (\pm)-DOI (10^{-12} – 10^{-3} M) were also performed in order to delineate both the G-protein coupled and uncoupled 5-HT_{2A}R conformations. Briefly, after incubation (60 min, 37 °C), free radioligand was discarded by rapid filtration under vacuum (1450 FilterMate Harvester, Perkin Elmer, Waltham, MA, USA). Filters were then rinsed, dried and bagged in Sample Bag with BetaPlate Scint scintillation cocktail. Radioactivity was detected by liquid scintillation spectrometry using a MicroBeta TriLux counter (Perkin Elmer, Waltham, MA, USA).

Antibody-capture [³⁵S]GTP γ S scintillation proximity assay (SPA)

Specific activation of different subtypes of G α -proteins by (\pm)-DOI (10 μ M) was determined using a previously described protocol [18]. The concentration of (\pm)-DOI (10 μ M) was chosen for being the one which induces stimulation values around the E_{max} for any G α subunit subtype under our experimental conditions [19]. [³⁵S]GTP γ S binding was performed in buffer containing 0.4 nM [³⁵S]GTP γ S, 15 μ g of protein/well and different GDP concentrations depending on the G α -subtype tested. Specific antibody for each G α -subunit and polyvinyltoluene SPA beads coated with protein-A were added and incubated (3 h, room temperature). Plates were centrifuged and bound radioactivity detected on a MicroBeta TriLux scintillation counter. Non-specific binding was defined as the remaining [³⁵S]GTP γ S binding in the presence of 100 μ M unlabeled GTP γ S. The antagonist ketanserin (10 μ M) was used to confirm the 5-HT_{2A}R involvement in the observed stimulations (data not shown).

Western blot

Western blot experiments were performed with total homogenate fractions (S1) from mouse brain cortex tissue. Samples (30 μ g) were heated (95 °C), loaded onto polyacrylamide gel (12%) and submitted to SDS-PAGE. Nitrocellulose membranes were blocked (5% non-fat dry-milk or/and 0.5% BSA) in TBS buffer followed by overnight incubation with primary antibodies (4 °C). Antibodies against 5-HT_{2A}R, Akt, phospho-Akt(Ser473), rpS6, phospho-rpS6 (Ser235/236) and β -actin were used. Incubation with fluorescent anti-IgG secondary antibodies was performed at room temperature (1 h). Immunoreactivity was quantified using an Odyssey




Fig. 1 Chronic THC treatment protocol and concentration. **a** Representation of the treatment design. **b** THC concentrations in mouse brain ($n = 6-8$) during treatment and after the washout period. Points represent individual data for each animal and lines represent means

Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA) (further details in Supplementary Table 1).

Data analysis and statistical procedures

Data were analyzed with GraphPad Prism™ 5.01, and InVivoStat software. Before the statistical analyses, the data were inspected for outliers (critical value, $Z > 1.96$) using Grubb's test (GraphPad Software, www.graphpad.com/quickcalcs/grubbs1.cfm). In PPI experiments, data from animals (between 0 and 3 animals per group) showing an outlier value for a particular dB or for the startle amplitude to the pulse were discarded for further analysis. Two animals were also discarded for not showing any response to the startle stimulus. Two-group comparisons were made by unpaired Student's *t*-test. Multiple groups' comparisons were studied by one-way, two-way or three-way analysis of variance (ANOVA), followed by Bonferroni's or Benjamini-Hochberg's post hoc analyses. Statistical significance was set at $p < 0.05$. Displacement curves were analyzed using a nonlinear fit, and the selection between models was made by the extrasum-of-squares (*F*-test). Following the nonlinear curve fitting, K_i values for (\pm)-DOI were calculated from the corresponding IC_{50} values. Differences in the binding profiles were assessed by unpaired Student's *t*-test of normalized (log) parameters. Specific binding values obtained from SPA assays were transformed to percentage of basal binding (binding values observed without agonist drug) obtained for each

α -protein and analyzed by one-sample or two-sample Student's *t*-test. The immunodensitometric values of the different target proteins were normalized to the intra-assay values obtained with anti- β -actin antibody and expressed as mean \pm SEM of the percentages over an inter-assay normalization sample included in every experiment. Each sample was analyzed at least in two independent experiments.

RESULTS

Time-dependent concentration of THC in mouse brain cortex
In order to validate the chronic administration protocol, brain THC concentrations were measured at treatment days 15 and 30, and after a 5-day washout period (Fig. 1a). THC reached 56 ng/g after 15 days of daily-chronic treatment. This concentration increased fourfold at day 30 (228 ng/g), while brain THC levels largely disappeared (6.05 ng/g) after the washout period (Fig. 1b).

Chronic THC potentiates (\pm)-DOI-induced decrease in PPI
Loss of PPI in rodents is considered a valid proxy for the study of the neurobiology of impaired sensorimotor gating in schizophrenia patients [20, 21]. Disruptions of the PPI response by acute administration of the 5-HT_{2A}R agonist (\pm)-DOI were evaluated in vehicle and THC-treated animals. We used a dose of 0.5 mg/kg (\pm)-DOI that has demonstrated, under our experimental




Fig. 2 Chronic THC increases the disruption of PPI induced by the 5-HT_{2A}R agonist (±)-DOI. **a** Chronic THC exacerbated the (±)-DOI-induced PPI disruption (three-way repeated measures ANOVA: THC × (±)-DOI; $F(1,51) = 6.48$, $p < 0.05$; $n = 8-16$). Benjamini-Hochberg's post hoc comparisons: * $p < 0.05$, ** $p < 0.01$ vs. vehicle. ### $p < 0.001$ vs. THC, \$\$ $p < 0.01$ vs. vehicle-DOI (see Supplementary Table 3 for further details on ANOVAs). **b** No differences were found in the startle amplitude among groups. Bars represent mean ± SEM




Fig. 3 Chronic THC does not modulate 5-HT_{2A}R protein density. **a** 5-HT_{2A}R immunodensity in brain total homogenates of vehicle- and THC-treated mice ($n = 8$ each group). Representative immunoblot of 5-HT_{2A}R and β-actin in vehicle and THC-treated mice. **b** Specific [³H]ketanserin binding saturation curves in cortical membranes of vehicle- and THC-treated mice (pool of $n = 8$ each group). Bars and points represent mean ± SEM

conditions, to induce a significantly decrease in the PPI (Supplementary Figure 1). Chronic THC significantly exacerbated the (±)-DOI-induced disruption of PPI (Fig. 2a). Chronic THC alone did not alter basal PPI, similar to previous findings [22]. No significant differences among groups were found in the amplitudes of the startle reflex (Fig. 2b).

Chronic THC does not alter total 5-HT_{2A}R density in brain cortex
Next, we investigated the effects of chronic THC on cortical 5-HT_{2A}R, the main molecular target of (±)-DOI. Protein immunodetection of 5-HT_{2A}R showed a single band at ~53 kDa, as previously described [23]. Chronic THC did not alter 5-HT_{2A}R protein expression (Fig. 3a). In order to confirm this result, saturation binding experiments with the 5-HT_{2A}R antagonist [³H]ketanserin were performed in brain cortical membranes. No significant differences in density (~340 fmol/mg protein) were observed between both groups (Fig. 3b).

Chronic THC modulates the functional coupling of cortical 5-HT_{2A}R

In order to deeper evaluate the molecular conformation of the 5-HT_{2A}R, we examined the pharmacological parameters of (±)-DOI displacing [³H]ketanserin binding in brain cortex membranes. The agonist (±)-DOI displaced the antagonist [³H]ketanserin binding in a biphasic manner (Fig. 4a). Comparing both the high- and low-affinity binding populations dissected by the agonist in vehicle- and THC-treated animals, the affinity of (±)-DOI for the high-affinity 5-HT_{2A}R population was significantly increased after chronic THC. No differences were found in any other pharmacological parameter (Supplementary Table 2).

We next evaluated the functionality of 5-HT_{2A}R by studying the agonist-induced functional coupling to different Gα-protein subtypes. The agonist (±)-DOI produced a selective activation of Gai1-, Gai3-, Gaz-, and Gaq/11-proteins but not of Gao- and Gas-proteins in vehicle-treated mice. The activation of all these




Fig. 4 Chronic THC promotes 5-HT_{2A}R signaling through inhibitory G-proteins. **a** Competition curve of [^3H]ketanserin specific binding (2 nM) by (\pm)-DOI in brain membranes of vehicle- and THC-treated mice (pool of $n = 8$ each group). In both cases, data were best fit to a biphasic compared to monophasic displacement curve (F -test, $p < 0.0001$, for both curves). (\pm)-DOI showed supersensitivity for the high-affinity subpopulation of 5-HT_{2A}R (** $p < 0.01$) (see Supplementary Table 2 for details) after chronic THC. **b** (\pm)-DOI (10 μM) induced Gai1-, Gai3-, Gao-, and Gaq/11-protein activation (* $p < 0.05$ vs. basal) in brain cortical membranes of vehicle-treated mice (pool of $n = 8$ each group). Chronic THC elicited a supersensitivity for (\pm)-DOI-induced Gai1-, Gai3-, Gao-, and Gaz protein activation (# $p < 0.05$ vs. vehicle). Points and bars represent mean \pm SEM of 4–6 different experiments carried out in triplicate. **c** Suggested model of the 5-HT_{2A}R signaling modulation after chronic THC

Ga-proteins was antagonized in the presence of ketanserin (10 μM) (data not shown). The Gai1/11-protein stimulation showed no significant differences between groups. By contrast, after THC chronic treatment, stimulation of Gai1-, Gai3-, Gao-, and Gai11-proteins by (\pm)-DOI was significantly increased. Stimulation of Gao-protein was only observed in THC-treated mice (Fig. 4b). Therefore, chronic THC exposure induced an overstimulation of inhibitory G-protein-mediated signaling (Fig. 4c).

Akt/mTOR signaling pathway is involved in the sensitization of 5-HT_{2A}R induced by chronic THC
In order to tackle the putative role of Akt/mTOR pathway in this functional modulation, mice were treated with both THC and the mTOR inhibitor rapamycin. Chronic THC significantly activated (increase of phosphorylated forms) immunoreactivity of both Akt and ribosomal protein S6 (rpS6), a downstream effector of mTOR, in cortical tissue. Moreover, this activation was abolished in the presence of rapamycin (Fig. 5a, b). Rapamycin also blocked the effect of THC treatment in the PPI response to (\pm)-DOI and restored it to vehicle-values (Fig. 5c), without changing the startle response (Fig. 5d). Finally, rapamycin treatment fully blocked the THC-induced hyperactivation of Gai1-, Gai3-, and Gaz-proteins by

(\pm)-DOI, but not that of Gao-protein (Fig. 5e). For the effects of chronic rapamycin alone, see Supplementary Figures 2–4.

DISCUSSION

Several pharmacological and behavioral effects of THC have been well documented in animal models, although little is known about the mechanism that promote psychosis-like behaviors [24]. Our study demonstrates under in vitro and in vivo conditions that chronic THC promotes a functional sensitization of 5-HT_{2A}R responses to the hallucinogenic agonist (\pm)-DOI. To our knowledge, these data provide the first evidence of a psychosis-like alteration of 5-HT_{2A}R signaling after chronic THC administration. Hallucinogenic effects of 5-HT_{2A}R agonists occurs by activation of inhibitory G-proteins [6, 19]. Thus, the specific alteration of agonist-induced signaling bias of 5-HT_{2A}R observed after THC may explain the higher susceptibility to psychosis-like states. In fact, an increased density of the functional conformation of 5-HT_{2A}R has been demonstrated in brain of schizophrenia patients [10]. On the other hand, THC is able to activate Akt/mTOR pathway [15]. Our results also demonstrate that this signaling pathway is implicated in the chronic THC-induced




Fig. 5 Akt/mTOR signaling pathway is involved in the THC-induced sensitization of 5-HT2AR signaling. Chronic THC increased phosphorylation of (a) Akt and (b) rpS6, and concomitant treatment with mTORC1 inhibitor rapamycin blocked these effects (one-way ANOVA: phospho-Akt/Akt ratio $F(2,20) = 15.68$, $p < 0.0001$; phospho-rpS6/rpS6 ratio $F(2,16) = 8.04$, $p < 0.01$; $n = 5-8$). Bonferroni's post hoc comparisons: * $p < 0.05$, ** $p < 0.01$ vs. vehicle. ### $p < 0.01$, #### $p < 0.001$ vs. THC. c Rapamycin blocked the sensitization to (±)-DOI effect on PPI in THC-treated mice, restoring it to vehicle-values among all the prepulses (three-way repeated measures ANOVA: THC × rapamycin; $F(1,35) = 4.50$, $p < 0.05$; $n = 8-16$). Benjamini-Hochberg's post hoc comparisons: * $p < 0.05$ vs. vehicle + DOI. # $p < 0.05$ vs. THC + DOI (see Supplementary Table 3 for further details on ANOVAs). Data of vehicle + DOI and THC + DOI groups are also in Fig. 2a. d No changes were found in the startle amplitude among groups. Data of vehicle + DOI and THC + DOI groups are also in Fig. 2b. e Rapamycin blocked the (±)-DOI-induced hyperactivation of Gαi1-, Gαi3-, and Gαz- (# $p < 0.05$, ## $p < 0.01$ vs. THC), but not that of Gαo proteins (pool of $n = 8$ each group). Bars represent mean ± SEM of 4-6 different experiments carried out in triplicate

modulation of 5-HT2AR functionality, since the mTOR inhibitor rapamycin blocked the sensitization.

Sensorimotor gating alterations are recognized as an endophenotype of schizophrenia [25] and loss-of-normal PPI occurs in schizophrenia patients [26]. PPI evaluation shows high-translational validity, as it can be assessed in both rodents and humans [20, 21, 27]. In line with other studies [22, 28], chronic THC per se does not alter sensorimotor gating process. However, decreases [29, 30] or no effects [31, 32] have been reported after

chronic synthetic cannabinoids administration (WIN55,212-2 or CP55,940). This discrepancy may be explained because distinct cannabinoid ligands can activate different G-protein subtypes [18]. At this point, as the main psychoactive component and the key player in the psychotomimetic effects of cannabis, the effects of THC should be considered as more representative of the alterations induced by chronic cannabis abuse in humans.

Interactions between the endocannabinoid and serotonergic systems have been widely reported in rodents and recently, a

CB1R-5-HT_{2A}R heterodimer has been proposed [33]. However, studies assessing cannabinoid effects on 5-HT_{2A}R functionality are limited. Chronic synthetic cannabinoids seem to potentiate (±)-DOI-mediated responses [34]; whereas, the acute administration of some cannabinoids inhibits (±)-DOI-induced head-twitch responses [35]. On the other hand, the antipsychotic risperidone, a 5-HT_{2A}R inverse agonist, reverses acute THC-induced PPI deficits [36]. Moreover, cannabis-induced psychosis in humans is also responsive to treatment with atypical antipsychotics [37]. Therefore, it seems that psychotic effect induced by acute THC should be differentiated from other modulation processes induced after chronic exposure.

Although disruptions of PPI after acute (±)-DOI administration are widely described [38, 39], our study demonstrates a marked supersensitivity to this disruption after chronic THC. The responses to (±)-DOI become increased together with an enhanced high-affinity conformation of the 5-HT_{2A}R. Classically, the high-affinity conformation of G-protein receptors is assumed as the functionally active state and represents the receptor fraction coupled to G-proteins [40]. Here, the enhanced coupling is selectively observed toward inhibitory G-proteins, which is considered the pro-hallucinogenic signaling pathway of this receptor. Accordingly, no changes were observed in total expression and density of 5-HT_{2A}R. In this context, an upregulation of cortical 5-HT_{2A}R mRNA and protein expression has been observed following a 7-day treatment with the synthetic cannabinoid CP55,940 [41]. However, as we observed in the present study, it has been described that chronic THC (10 mg/kg) do not modulate 5-HT_{2A}R density in mice brain [42]. This fact supports again the use of THC, rather than other cannabinoid ligand, to evaluate the effects of cannabis abuse. The washout period becomes crucial in studies assessing chronic effects of cannabinoids, as they are able to accumulate in adipose tissue and may induce effects due to the residual presence of the drug. Our data about THC brain concentrations reached during treatment strongly support that the observed effects were due to enduring brain changes derived from the chronic exposure to THC.

The present is the first demonstration that chronic THC leads to supersensitive coupling of 5-HT_{2A}R to inhibitory G-proteins whereas Gαq/11-protein signaling pathway remains unaltered. 5-HT_{2A}R canonically activates phospholipase C via Gαq/11-proteins but it can also activate phospholipase A₂, as well as other G-protein subtypes, depending on the ligand used [43]. Hallucinogenic and non-hallucinogenic serotonergic drugs activate the same population of 5-HT_{2A}R in cortical pyramidal neurons, but differ in the receptor-dependent pattern of G-protein signaling and gene transcription induction that they elicit. In human and murine cortical neurons, non-hallucinogenic 5-HT_{2A}R agonists induce *c-fos* expression mediated by Gαq/11-protein-dependent phospholipase C activation. In contrast, hallucinogen 5-HT_{2A}R agonists such as (±)-DOI or LSD, acting at the 5-HT_{2A}R, not only activate *c-fos* but also induce *egr-2* expression, which is a Gαi/o-protein-dependent response. This signaling pattern has been proposed as a specific fingerprint of hallucinogenic pharmacological properties [44].

Although further testing is needed, the selective overactivation of inhibitory G-proteins by (±)-DOI after THC treatment provides a crucial aspect regarding how chronic THC exposure could increase vulnerability to psychosis. Remarkably, selective hypersensitive 5-HT_{2A}R coupling to Gαi/o proteins has also been demonstrated in post mortem frontal cortex of schizophrenia patients [45].

Our results also demonstrate the involvement of the Akt/mTOR signaling pathway in the molecular mechanisms underlying the THC-induced modulation of 5-HT_{2A}R. Rapamycin inhibits mTOR complex 1 (mTORC1), a protein complex that plays an important role in protein synthesis, cell-cycle progression, cell growth and proliferation [46, 47]. The protein kinase Akt activates mTORC1 that subsequently activates ribosomal protein S6, and regulates axonal branching [11]. This complex has been involved

in THC-induced memory deficits [15]. Moreover, polymorphisms in the *AKT1* gene are known to increase cannabis-induced psychotic responses [48, 49]. Interestingly, ablation of both phospho (Ser473)-Akt and S6 kinase (S6K), whose target substrate is the S6 ribosomal protein, is able to alter 5-HT_{2A}R functionality and signaling [50]. Our data demonstrate that rapamycin prevents the THC-induced activation of Akt/mTOR pathway and restores the alterations in the 5-HT_{2A}R functionality. Nonetheless, the involvement of other signaling pathways, as well as the modulation of other cellular mechanisms induced by the chronic administration of rapamycin cannot be discarded.

In summary, the present study demonstrates that chronic THC exposure leads to the overactivation of a pro-hallucinogenic signaling pathway of 5-HT_{2A}R through the regulation of Akt/mTOR pathway. Findings of the present work describe, for the first time, the molecular mechanisms underlying the link between cannabis abuse and susceptibility to schizophrenia-like symptoms.

ACKNOWLEDGEMENTS

The authors would like to thank Dr. Arkaitz Carracedo for scientific advice regarding rapamycin experiments and the human and technical support provided by the Central Service of Analysis of Alava -SGlker- of UPV/EHU. L.U., R.D.-A. and L.F.C. designed experiments. I.I.-L., L.U., and J.J.M. wrote the manuscript. Chronic treatments were performed by I.I.-L. Behavioral experiments were performed by I.I.-L. and I.M.-G. with assistance from L.U. Biochemical assays were performed by I.I.-L. and R.D.-A. All the contributors revised critically and gave their approval to the final version of the manuscript. This study was funded by the Instituto de Salud Carlos III, FEDER (PI13/01529 to L.U.) and the Basque Government (IT616/13 to J.J.M.). I.I.-L. and I.M.-G. are recipients of Predoctoral Fellowships from the Basque Government and the University of the Basque Country, respectively.

ADDITIONAL INFORMATION

Supplementary information accompanies this paper at (<https://doi.org/10.1038/s41386-018-0076-y>)

Competing interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. *BMJ*. 2002;325:1212–3.
2. Di Forti M, Marconi A, Carra E, Faraone S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. *Lancet Psychiatry*. 2015;2:233–8.
3. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. *Lancet*. 2009;374:1383–91.
4. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. *Am J Psychiatry*. 2010;167:987–93.
5. Nichols DE. Psychedelics. *Pharmacol Rev*. 2016;68:264–355.
6. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. *Neuron*. 2007;53:439–52.
7. Abdolmaleky HM, Yaqubi S, Papageorgis P, Lambert AW, Ozturk S, Sivaraman V, et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. *Schizophr Res*. 2011;129:183–90.
8. Malkova NV, Gallagher JJ, Yu CZ, Jacobs RE, Patterson PH. Manganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia. *Proc Natl Acad Sci USA*. 2014;111:E2492–500.
9. Santini MA, Ratner C, Aznar S, Klein AB, Knudsen GM, Mikkelsen JD. Enhanced prefrontal serotonin 2A receptor signaling in the subchronic phencyclidine mouse model of schizophrenia. *J Neurosci Res*. 2013;91:634–41.
10. Muguruza C, Moreno JL, Umali A, Callado LF, Meana JJ, Gonzalez-Maeso J. Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. *Eur Neuropsychopharmacol*. 2013;23:852–64.

11. Grider MH, Park D, Spencer DM, Shine HD. Lipid raft-targeted Akt promotes axonal branching and growth cone expansion via mTOR and Rac1, respectively. *J Neurosci Res.* 2009;87:3033–42.
12. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. *Nat Genet.* 2004;36:131–7.
13. Gururajan A, van den Buuse M. Is the mTOR-signalling cascade disrupted in Schizophrenia? *J Neurochem.* 2014;129:377–87.
14. Morgan CJ, Freeman TP, Powell J, Curran HV. AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. *Transl Psychiatry.* 2016;6:e738.
15. Puighermanal E, Busquets-García A, Gomis-González M, Marsicano G, Maldonado R, Ozaita A. Dissociation of the pharmacological effects of THC by mTOR blockade. *Neuropsychopharmacol.* 2013;38:1334–43.
16. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. *J Clin Invest.* 2008;118:3065–74.
17. Kurita M, Holloway T, García-Bea A, Kozlenkov A, Friedman AK, Moreno JL, et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. *Nat Neurosci.* 2012;15:1245–54.
18. Diez-Alarcia R, Ibarra-Lecue I, Lopez-Cardona AP, Meana J, Gutierrez-Adan A, Callado LF, et al. Biased agonism of three different cannabinoid receptor agonists in mouse brain cortex. *Front Pharmacol.* 2016;7:415.
19. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. *Nature.* 2008;452:93–97.
20. Powell SB, Zhou X, Geyer MA. Prepulse inhibition and genetic mouse models of schizophrenia. *Behav Brain Res.* 2009;204:282–94.
21. Swerdlow NR, Braff DL, Taaib N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. *Arch Gen Psychiatry.* 1994;51:139–54.
22. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T. Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. *Int J Neuropsychopharmacol.* 2013;16:163–75.
23. Aira Z, Buesa I, García del Cano G, Salgueiro M, Mendiola N, Mingo J, et al. Selective impairment of spinal mu-opioid receptor mechanism by plasticity of serotonergic facilitation mediated by 5-HT2A and 5-HT2B receptors. *Pain.* 2012;153:1418–25.
24. Rubino T, Parolaro D. The impact of exposure to cannabinoids in adolescence: insights from animal models. *Biol Psychiatry.* 2016;79:578–85.
25. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. *Arch Gen Psychiatry.* 1990;47:181–8.
26. Ludwig K, Geyer MA, Vollenweider FX. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. *Biol Psychiatry.* 2003;54:121–8.
27. Halberstadt AL, Geyer MA. Effect of Hallucinogens on Unconditioned Behavior. *Current Topics in BehavioralNeurosciences.* Berlin, Heidelberg: Springer; 2016. p. 1–41.
28. Silva L, Black R, Michaelides M, Hurd YL, Dow-Edwards D. Sex and age specific effects of delta-9-tetrahydrocannabinol during the periadolescent period in the rat: The unique susceptibility of the prepubescent animal. *Neurotoxicol Teratol.* 2016;58:88–100.
29. Klein J, Hadar R, Gotz T, Manner A, Eberhardt C, Baldassarri J, et al. Mapping brain regions in which deep brain stimulation affects schizophrenia-like behavior in two rat models of schizophrenia. *Brain Stimul.* 2013;6:490–9.
30. Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. *Neuropsychopharmacology.* 2003;28:1760–9.
31. Llorente-Berzal A, Fuentes S, Gagliano H, Lopez-Gallardo M, Armario A, Viveros MP, et al. Sex-dependent effects of maternal deprivation and adolescent cannabinoid treatment on adult rat behaviour. *Addict Biol.* 2011;16:624–37.
32. Bortolato M, Aru GN, Frau R, Orru M, Luckey GC, Boi G, et al. The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. *Psychopharmacology.* 2005;177:264–71.
33. Galindo L, Moreno E, Lopez-Armenta F, Guinart D, Cuenca-Royo A, Izquierdo-Serra M, et al. Cannabis Users Show Enhanced Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium Cells. *Mol Neurobiol.* 2018; <https://doi.org/10.1007/s12035-017-0833-7>.
34. Hill MN, Sun JC, Tse MT, Gorzalka BB. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. *Int J Neuropsychopharmacol.* 2006;9:277–86.
35. Darmani NA. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. *Pharmacol Biochem Behav.* 2001;68:311–7.
36. Nagai H, Egashira N, Sano K, Ogata A, Mizuki A, Mishima K, et al. Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. *Pharmacol Biochem Behav.* 2006;84:330–6.
37. Berk M, Brook S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. *Int Clin Psychopharmacol.* 1999;14:177–80.
38. de Oliveira RP, Nagaishi KY, Barbosa Silva RC. Atypical antipsychotic clozapine reversed deficit on prepulse inhibition of the acoustic startle reflex produced by microinjection of DOI into the inferior colliculus in rats. *Behav Brain Res.* 2017;325:72–78.
39. Farid M, Martinez ZA, Geyer MA, Swerdlow NR. Regulation of sensorimotor gating of the startle reflex by serotonin 2A receptors. Ontogeny and strain differences. *Neuropsychopharmacology.* 2000;23:623–32.
40. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist specific binding properties of the adenylylate cyclase-coupled beta-adrenergic receptor. *J Biol Chem.* 1980;255:7108–17.
41. Franklin JM, Carrasco GA. Cannabinoid-induced enhanced interaction and protein levels of serotonin 5-HT(2A) and dopamine D(2) receptors in rat prefrontal cortex. *J Psychopharmacol.* 2012;26:1333–47.
42. Dowie MJ, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. *Neuroscience.* 2010;170:324–36.
43. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE. Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. *J Pharmacol Exp Ther.* 2003;304:229–37.
44. Gonzalez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, et al. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. *J Neurosci.* 2003;23:8836–43.
45. Meana J, Miranda-Azpiazu P, Garcia-Bea A, Muguruza C, Callado L, Gabilondo A, et al. Selective up-regulation of serotonin 5-HT2A receptor coupling to G alpha (i1)-proteins in postmortem brain of subjects with schizophrenia. *Eur Neuropsychopharmacol.* 2014;24:5483–4.
46. Wullschlegel S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell.* 2006;124:471–84.
47. Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. *Cell Metab.* 2014;19:373–9.
48. Di Forti M, Iyegbe C, Sallis H, Koliakou A, Falcone MA, Paparelli A, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. *Biol Psychiatry.* 2012;72:811–6.
49. van Winkel R, Genetic R, Outcome of Psychosis I. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. *Arch Gen Psychiatry.* 2011;68:148–57.
50. Strachan RT, Sciaky N, Cronan MR, Kroeze WK, Roth BL. Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity. *Mol Pharmacol.* 2010;77:327–38.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.